The increasing incidence of cancer is a significant driver influencing the market progress. Cancer has emerged as a global health challenge, with a steadily increasing burden of new cancer cases reported each year. For instance, according to the American Cancer Society, around 1.9 million new cancer cases are expected to be diagnosed in the U.S. alone in 2023, and approximately 609,820 cancer-related fatalities, which is about 1,670 deaths per day. Thus, usage of whole genome sequencing enables the identification of genetic mutations associated with an increased risk of developing certain types of cancer.
Also, by studying the genomic data of individuals with a family history of cancer or those diagnosed at a young age, researchers can identify cancer susceptibility genes. This information is crucial for understanding cancer diagnostics, and implementing preventive measures or treatment regimes. Furthermore, the pharmaceutical companies also rely on genomic information to develop and test oncology drugs, leading to an increasing demand for whole genome sequencing.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The whole genome sequencing (WGS) market size was valued to be USD 5.5 billion in 2022 and is expected to surpass USD 30 billion by 2032 driven by increasing prevalence of genetic disorders.
The consumables segment is expected to reach USD 18.1 billion by 2032, due to the use of consumables in large quantities in every step of the sequencing process.
In 2022, North America whole genome sequencing market was valued at USD 2.5 billion and will continue to grow, is majorly attributed to the increasing research institutions, universities, and medical centers in the region.